한글목차

지단홍통증 치료의 동향과 예측

세계의 지단홍통증 치료 시장은 2024-2030년 CAGR 5.8%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 지단홍통증 환자의 증가, 정밀의료에 대한 투자의 증가, Drug Discovery 기술의 진보입니다. 세계의 지단홍통증 치료 시장의 미래는 병원, 재택의료, 전문 클리닉의 각 시장에서의 기회에 의해 유망시되고 있습니다.

지단홍통증 치료 시장 인사이트

Lucintel의 예측에 따르면 예측 기간 중 지단홍통증의 증상 관리에 유효한 약제가 입수하기 쉬운 것으로 인해 약물 요법이 계속 큰 부문을 차지합니다.

지단홍통증 환자에게 종합적 치료를 제공하기 위한 인프라와 전문 지식의 필요성이 높아지고 있으므로 이 시장내에서는 병원이 최대 부문을 유지할 것으로 생각됩니다.

북미는 연구 대학, 의학부, 제약회사 수가 증가하고 있으므로 예측 기간 중에도 최대 지역입니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품은 무엇이며, 재료 및 제품의 대체에 의한 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 지단홍통증 치료 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 지단홍통증 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 치료별 세계의 지단홍통증 치료 시장
  • 약제
  • 수술
• 유형별 세계의 지단홍통증 치료 시장
  • 원발성 홍반 통증
  • 연발성 홍반 통증
• 약제별 세계의 지단홍통증 치료 시장
  • Lidocaine
  • Capsaicin
  • Diclofenac
  • Brimonidine
  • Misoprostol
  • 기타
• 최종 용도별 세계의 지단홍통증 치료 시장
  • 병원
  • 홈케어
  • 전문 클리닉
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 지단홍통증 치료 시장
• 북미의 지단홍통증 치료 시장
• 유럽의 지단홍통증 치료 시장
• 아시아태평양의 지단홍통증 치료 시장
• 기타 지역지단홍통증 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 치료별 세계의 지단홍통증 치료 시장의 성장 기회
  • 유형별 세계의 지단홍통증 치료 시장의 성장 기회
  • 약제별 세계의 지단홍통증 치료 시장의 성장 기회
  • 최종 용도별 세계의 지단홍통증 치료 시장의 성장 기회
  • 지역별 세계의 지단홍통증 치료 시장의 성장 기회
• 세계의 지단홍통증 치료 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 지단홍통증 치료 시장의 능력 확대
  • 세계의 지단홍통증 치료 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Teva Pharmaceutical Industries
• Xenon
• Biogen
• ICAGEN
• Pfizer
• Zydus Cadila
• ANI Pharmaceuticals

영문목차

Erythromelagia Treatment Trends and Forecast

The future of the global erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine, and advancement in drug discovery technologies.

A more than 150-page report is developed to help in your business decisions.

Erythromelagia Treatment by Segment

The study includes a forecast for the global erythromelagia treatment by treatment, type, drug, end-use, and region.

Erythromelagia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Medication
• Surgery

Erythromelagia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Primary Erythromelalgia
• Secondary Erythromelalgia

Erythromelagia Treatment Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

• Lidocaine
• Capsaicin
• Diclofenac
• Brimonidine
• Misoprostol
• Others

Erythromelagia Treatment Market by End-Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Erythromelagia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Erythromelagia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies erythromelagia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the erythromelagia treatment companies profiled in this report include-

• Teva Pharmaceutical Industries
• Xenon
• Biogen
• ICAGEN
• Pfizer
• Zydus Cadila
• ANI Pharmaceuticals

Erythromelagia Treatment Market Insights

Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Within this market, hospital will remain the largest segment due to growing need of infrastructure and expertise to provide comprehensive care for patients with erythromelalgia.

North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Features of the Global Erythromelagia Treatment Market

Market Size Estimates: Erythromelagia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Erythromelagia treatment market size by various segments, such as by treatment, type, drug, end-use, and region in terms of value ($B).

Regional Analysis: Erythromelagia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, types, drugs, end-uses, and regions for the erythromelagia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the erythromelagia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for erythromelagia treatment market?

Answer: The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the erythromelagia treatment market?

Answer: The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine and advancement in drug discovery technologies.

Q3. What are the major segments for erythromelagia treatment market?

Answer: The future of the erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q4. Who are the key erythromelagia treatment market companies?

Answer: Some of the key erythromelagia treatment companies are as follows:

• Teva Pharmaceutical Industries
• Xenon
• Biogen
• ICAGEN
• Pfizer
• Zydus Cadila
• ANI Pharmaceuticals

Q5. Which erythromelagia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Q6. In erythromelagia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the erythromelagia treatment market by treatment (medication and surgery), type (primary erythromelalgia and secondary erythromelalgia), drug (lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, and others), end-use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Erythromelagia Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Erythromelagia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Erythromelagia Treatment Market by Treatment
  • 3.3.1: Medication
  • 3.3.2: Surgery
• 3.4: Global Erythromelagia Treatment Market by Type
  • 3.4.1: Primary Erythromelalgia
  • 3.4.2: Secondary Erythromelalgia
• 3.5: Global Erythromelagia Treatment Market by Drug
  • 3.5.1: Lidocaine
  • 3.5.2: Capsaicin
  • 3.5.3: Diclofenac
  • 3.5.4: Brimonidine
  • 3.5.5: Misoprostol
  • 3.5.6: Others
• 3.6: Global Erythromelagia Treatment Market by End-Use
  • 3.6.1: Hospitals
  • 3.6.2: Homecare
  • 3.6.3: Specialty Clinics
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Erythromelagia Treatment Market by Region
• 4.2: North American Erythromelagia Treatment Market
  • 4.2.2: North American Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Erythromelagia Treatment Market
  • 4.3.1: European Erythromelagia Treatment Market by Treatment: Medication and Surgery
  • 4.3.2: European Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Erythromelagia Treatment Market
  • 4.4.1: APAC Erythromelagia Treatment Market by Treatment: Medication and Surgery
  • 4.4.2: APAC Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Erythromelagia Treatment Market
  • 4.5.1: ROW Erythromelagia Treatment Market by Treatment: Medication and Surgery
  • 4.5.2: ROW Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Erythromelagia Treatment Market by Treatment
  • 6.1.2: Growth Opportunities for the Global Erythromelagia Treatment Market by Type
  • 6.1.3: Growth Opportunities for the Global Erythromelagia Treatment Market by Drug
  • 6.1.4: Growth Opportunities for the Global Erythromelagia Treatment Market by End-Use
  • 6.1.5: Growth Opportunities for the Global Erythromelagia Treatment Market by Region
• 6.2: Emerging Trends in the Global Erythromelagia Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Erythromelagia Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Erythromelagia Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Teva Pharmaceutical Industries
• 7.2: Xenon
• 7.3: Biogen
• 7.4: ICAGEN
• 7.5: Pfizer
• 7.6: Zydus Cadila
• 7.7: ANI Pharmaceuticals